X
MDGL icon

Xponance’s Madrigal Pharmaceuticals MDGL Stock Holding History

Xponance’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59M Buy
2,958
+1,332
+82% +$682K 0.01% 654
2026
Q1 		$851K Buy
1,626
+163
+11% +$77.9K 0.01% 800
2025
Q4 		$852K Buy
1,463
+3
+0.2% +$1.53K 0.01% 738
2025
Q3 		$670K Buy
1,460
+152
+12% +$56.7K 0.01% 858
2025
Q2 		$396K Sell
1,308
-51
-4% -$15.2K ﹤0.01% 1035
2025
Q1 		$450K Buy
1,359
+91
+7% +$29.9K ﹤0.01% 971
2024
Q4 		$391K Buy
1,268
+113
+10% +$31.8K ﹤0.01% 1032
2024
Q3 		$245K Buy
1,155
+38
+3% +$9.72K ﹤0.01% 1155
2024
Q2 		$313K Buy
1,117
+224
+25% +$53.3K ﹤0.01% 1046
2024
Q1 		$238K Buy
893
+2
+0.2% +$471 ﹤0.01% 1132
2023
Q4 		$206K Buy
+891
New +$156K ﹤0.01% 1150
2023
Q1 		– Sell
-729
Closed -$212K – 1249
2022
Q4 		$212K Buy
+729
New +$71.3K ﹤0.01% 1113

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Xponance's MDGL Position: Q2 2026 in Review

Xponance increased its Madrigal Pharmaceuticals (MDGL) stake by 82% in Q2 2026, buying an estimated $682K and bringing the position to 2,958 shares worth $1.59M. The position accounts for 0.01% of the portfolio, ranked #654.

Xponance first reported a position in MDGL in Q4 2022 and has held it in 12 quarters since. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Xponance held 2,958 shares of Madrigal Pharmaceuticals worth $1.59M as of Q2 2026.
  • Xponance bought 1,332 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $682K.
  • Madrigal Pharmaceuticals made up 0.01% of Xponance's portfolio in Q2 2026, its #654 holding.
  • Xponance first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.